Neuroproteomics in Epilepsy: What Do We Know so Far?

21Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Epilepsies are chronic neurological diseases that affect approximately 2% of the world population. In addition to being one of the most frequent neurological disorders, treatment for patients with epilepsy remains a challenge, because a proportion of patients do not respond to the antiseizure medications that are currently available. This results in a severe economic and social burden for patients, families, and the healthcare system. A characteristic common to all forms of epilepsy is the occurrence of epileptic seizures that are caused by abnormal neuronal discharges, leading to a clinical manifestation that is dependent on the affected brain region. It is generally accepted that an imbalance between neuronal excitation and inhibition generates the synchronic electrical activity leading to seizures. However, it is still unclear how a normal neural circuit becomes susceptible to the generation of seizures or how epileptogenesis is induced. Herein, we review the results of recent proteomic studies applied to investigate the underlying mechanisms leading to epilepsies and how these findings may impact research and treatment for these disorders.

Cite

CITATION STYLE

APA

do Canto, A. M., Donatti, A., Geraldis, J. C., Godoi, A. B., da Rosa, D. C., & Lopes-Cendes, I. (2021, January 7). Neuroproteomics in Epilepsy: What Do We Know so Far? Frontiers in Molecular Neuroscience. Frontiers Media S.A. https://doi.org/10.3389/fnmol.2020.604158

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free